MOH — authorised 31 July 2014
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Status: likely_approved
MOH authorised Striverdi Respimat on 31 July 2014
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 31 July 2014.
BOEHRINGER INGELHEIM holds the UAE marketing authorisation.